Thomas W. LeBlanc, MD, MA, MHS and Arif H. Kamal, MD, MBA, MHS
Clinical trials should assess patients’ distress and test interventions to address it, just as they assess adverse events and test novel therapeutic agents.
AMA J Ethics. 2017;19(5):460-466. doi:
10.1001/journalofethics.2017.19.5.stas1-1705.
Amy Barnhorst, MD, Garen Wintemute, MD, MPH, and Marian E. Betz, MD, MPH
When mandatory reporting of risk of violence is not required, physicians should balance patient autonomy and beneficence with patient and public safety.
AMA J Ethics. 2018;20(1):29-35. doi:
10.1001/journalofethics.2018.20.1.ecas1-1801.
Developing drugs for profit is challenged in Parasites!, a patient education comic that highlights the need for unprofitable drugs for tropical diseases.
AMA J Ethics. 2018;20(2):167-175. doi:
10.1001/journalofethics.2018.20.2.msoc1-1802.
AMA Journal of Ethics editor Audiey Kao, MD, PhD, interviewed Richard Pan, MD, MPH, about how, as a physician and legislator, he seeks to protect public health in light of recurrent outbreaks of vaccine-preventable infectious diseases.
Meera Balasubramaniam, MD, MPH and Yesne Alici, MD
A 15-year-old advance directive made when the patient was in much better health and not updated can bring more confusion than clarity to the decision-making process.
A 15-year-old advance directive made when the patient was in much better health and not updated can bring more confusion than clarity to the decision-making process.